Q2 Fiscal Year 2020 Comparable revenue growth of 3.3% – negative COVID-19 impact of about 4 percentage points Strong revenue performance in Imaging with 5.8% comparable growth and Advanced Therapies with 5.7% increase These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures (financial key performance indicators) that are or may be alternative performance measures (non-GAAP-measures).
The Conference Call for journalists was broadcast live. The Conference Call for journalists was broadcast live.

Bernd Montag - …

Earnings Release and Financial Results Q2 FY 2020: Robust performance in complicated times Revenue was €14.2 billion, nearly level with the same quarter a year ago, as increases at Siemens Healthineers and Mobility offset a decline at Digital Industries; orders declined 8%, to €15.1 billion, on sharply lower volume from large orders at Mobility Be the first to know about our events, trainings and news. Would you like to provide detailed feedback? This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. Nevertheless, the fundamental growth drivers of our business remain intact.". Be the first to know about our events, trainings and news. We released our second quarter results for fiscal year 2020 on May 5, 2020. The information contained in this document is provided as of the date of its publication and is subject to change without notice. As of beginning of fiscal year 2020, Siemens Healthineers applies the accounting standard IFRS 16, Leases. Bernd Montag, CEO of Siemens Healthineers AG:"We stand shoulder to shoulder with our customers as a strong partner during the global COVID-19 pandemic. Would you like to provide detailed feedback? As they relate to future events or developments, these statements are subject to a various risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. In addition, our representatives may from time to time make oral forward-looking statements. The Conference Call for journalists was broadcast live.

Erlangen, Germany | 

Additional information on reconciliations is also included in the Analyst Presentation. Note: to get a direct personal response, please, First quarter results for fiscal year 2020, Integrated Immunoassay and Chemistry Analyzers, Answering the call to address the Coronavirus pandemic, Digital solutions for clinical specialties, Supporting operational, clinical, and shared decision-making along the patient pathway, Get the Facts About Biotin Interference in Immunoassays, Medical Imaging & Therapy Systems Education, Healthy Mother/Healthy Baby Thought Leadership Webinar Series, IHE - Integrating the Healthcare Enterprise, External Innovation Think Tank (eITT) Exhibition 2020, Siemens Healthineers at VIRTUAL EUROSPINE 2020, H-ISAC Virtual Healthcare Security Workshop, Siemens Healthineers Talks - COVID-19 Edition, The Beryl Institute Patient Experience Conference 2020, World Medical Innovation Forum - WMIF 2019, Siemens Healthineers starts new fiscal year with strong growth – outlook confirmed, Analyst Presentation of Bernd Montag, Jochen Schmitz, Press Release: Siemens Healthineers Wins Bid to Become Primary Supplier for Quest Diagnostics Immunoassay Testing with Atellica Solution, philipp.grontzki@siemens-healthineers.com. Healthineers post Q2 FY2020 Consensus for FY2020 - FY2023 - May 25, 2020 (xlsx) 0.1 MB First-quarter results FY2020 I Feb 3, 2020 On February 3rd the conference call for analysts and investors with CEO Dr. Bernd Montag and CFO Dr. Jochen Schmitz was broadcast via audio webcast.

Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. Would you like to provide detailed feedback? Overall, our business has performed well in the second quarter despite the pandemic and growing economic turbulence around the globe. Presentation Q3 FY2020 - Aug 2, 2020 (pdf) 2.46 MB Quarterly Statement Q3 FY2020 - Aug 2, 2020 (pdf) 0.18 MB Healthineers post Q3 FY2020 Consensus for FY2020 - FY2023 - Sept. 1, 2020 (xlsx) 0.1 MB 2.2% in Diagnostics in light of a declining number of patients due to the crisis burdens profitability, Adjusted EBIT margin at 17.9%, +10 bps year on year and clear improvement from Q1, Adjusted basic earnings per share rise 11% to €0.45, Q2 free cash flow resilient but below Q1 due to crisis-related inventory build-up, Outlook for FY 2020 no longer valid, Q3 expected to be trough. Q2 2020 Earnings Conference Call.

Note: to get a direct personal response, please, Siemens Healthineers with strong second-quarter performance despite COVID-19 pandemic, Integrated Immunoassay and Chemistry Analyzers, Answering the call to address the Coronavirus pandemic, Digital solutions for clinical specialties, Supporting operational, clinical, and shared decision-making along the patient pathway, Get the Facts About Biotin Interference in Immunoassays, Medical Imaging & Therapy Systems Education, Healthy Mother/Healthy Baby Thought Leadership Webinar Series, IHE - Integrating the Healthcare Enterprise, External Innovation Think Tank (eITT) Exhibition 2020, Siemens Healthineers at VIRTUAL EUROSPINE 2020, H-ISAC Virtual Healthcare Security Workshop, Siemens Healthineers Talks - COVID-19 Edition, The Beryl Institute Patient Experience Conference 2020, World Medical Innovation Forum - WMIF 2019, https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications, philipp.grontzki@siemens-healthineers.com, Comparable revenue growth of 3.3% – negative COVID-19 impact of about 4 percentage points, Strong revenue performance in Imaging with 5.8% comparable growth and Advanced Therapies with 5.7% increase, Equipment book-to-bill with 0.94 only slightly below 1, Revenue decline by comp.
Stefan SchmidtKarlheinz Kaske Straße 591052 ErlangenGermany, +49 152 02307361stefanssschmidt@siemens-healthineers.com, Philipp GrontzkiKarlheinz Kaske Straße 591052 ErlangenGermany, +49 152 03350194philipp.grontzki@siemens-healthineers.com. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning.

... stefanssschmidt@siemens-healthineers.com.

May 5, 2020 02:00 ET. We released our first quarter results for fiscal year 2020 on February 3, 2020.

As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Chief Executive Officer, Siemens Healthineers, Chief Financial Officer, Siemens Healthineers, Stefan SchmidtKarlheinz Kaske Straße 591052 ErlangenGermany, +49 152 02307361stefanssschmidt@siemens-healthineers.com, Philipp GrontzkiKarlheinz Kaske Straße 591052 ErlangenGermany, +49 152 03350194philipp.grontzki@siemens-healthineers.com, +49 162 2433492ulrich.kuenzel@siemens-healthineers.com. Q2 Documents Siemens Healthineers with strong second-quarter performance despite COVID-19 pandemic Please find further explanations to our financial key performance indicators in chapter „A.2 Financial performance system“ and in the notes to the consolidated financial statements note 29 „Segment information“ in the Annual Report 2019 of Siemens Healthineers. In case of discrepancies, the German language document is the sole authoritative and universally valid version. We have increased our profitability from the first quarter, and thereby kept the promise we made. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. These documents are available under the following internet link https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications. First quarter results for fiscal year 2020 Feb 03, 2020. We released our second quarter results for fiscal year 2020 on May 5, 2020. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable. Marc Koebernick - Head, Investor Relations.

We released our first quarter results for fiscal year 2020 on February 3, 2020.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. Currently, there are no reliable forecasts for the duration or intensity of the COVID-19 pandemic. This document is an English language translation of the German document.


Anthony Joshua Net Worth 2019, St Thomas Hospital Physician Directory, Sulayman Chappelle Birthday, The Mummy Cast 2017, James De Givenchy, Positive Feedback Psychology Definition, Best Bbc Documentaries 2020, Ring Doorbell Coupon Code 2020, Allen Leech Downton Abbey, Similarities Between Spain And The United States Education, How To Reset Ring Doorbell Pro, Fiorentina Fc, Rafael Nadal Net Worth In Rupees, Rochester Knighthawks Logo, Italian Vs Colombian Coffee, Wedding Venues In Nj, Bridge To Terabithia Characters, Fiona Kitschin, Before The Devil Knows You're Dead Opening Scene, Jeremy Irvine Partner, Geek Squad Jobs, Marshall Teague Nascar,